Response of dermatomyositis to the antimalarial quinacrine: A retrospective cohort study - 10/03/21
Doi : 10.1016/j.jaad.2020.07.081
Adarsh Ravishankar, BS a, b, Daisy Yan, BA a, b, Christina E. Bax, BA a, b, Josef S. Concha, MD a, b, Rui Feng, PhD c, Victoria P. Werth, MD a, b, ⁎ 
a Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania
b Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
c Department of Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania
∗Correspondence to: Victoria P. Werth, MD, Department of Dermatology, Perelman Center for Advanced Medicine, Suite 1-330A, 3400 Civic Center Blvd, Philadelphia, PA 19104Department of DermatologyPerelman Center for Advanced MedicineSuite 1-330A, 3400 Civic Center BlvdPhiladelphiaPA19104
| Funding sources: Supported by the U.S. Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development and Biomedical Laboratory Research and Development) (to Dr Werth) and the Center for Advancing Translational Sciences of the National Institutes of Health, TL1TR001880 (to Author Bax). |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: IRB approval has been obtained for the dermatomyositis patient database used in this study (University of Pennsylvania IRB 808230). |
|
| Reprints not available from the authors. |
© 2020
Publié par Elsevier Masson SAS.
Vol 84 - N° 4
P. 1157-1160 - avril 2021 Retour au numéro
Article précédent
- Serologic characterization of anti-p200 pemphigoid: Epitope spreading as a common phenomenon
- Maike M. Holtsche, Stephanie Goletz, Anabelle von Georg, Nina van Beek, Franziska Hübner, Manuela Pigors, Detlef Zillikens, Enno Schmidt
- A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis
- Yoo Jung Kim, Elena Schiopu, Katalin Dankó, Tahseen Mozaffar, Srinivas Chunduru, Kirstin Lees, Namita A. Goyal, Jeffrey Sarazin, David F. Fiorentino, Kavita Y. Sarin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?